1Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J] CA Cancer J Clin,2005,55(2):74-108.
2Mountain CF.Revisions in the International System for Staging Lung Cancer[J].Chest,1997,111(6):1710-1717.
3Fischer BM,Mortensen J.The future in diagnosis and staging of lung cancer,positron emission tomography[J].Respiration,2006,73(3):267-276.
4Pieterman RM,van Putten JW,Meuzelaar J J,et al.Preoperative staging of non-small-cell lung cancer with positron-emission tomography[J].N Engl J Mad,2000,343(4):254-261.
5Weber WA,Petersen V,Schmidt B,et al.Positron emission tomography in non-small-cell lung cancer:prediction of response to chemotherapy by quantitative assessment of glucose use[J].J Clin Oncol,2003,21(14):2651-2657.
6Duffand F,Therasse F.New guidelines to evaluate the response to treatment in solid tumors[J].Bull Cancer,2000,87(12):881-816.
7Nahmias C,Hanna WT,Wahl LM,et al.Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT[J].J Nucl Med,2007,48(5):744-751.
8Mac Mantis MP,Hicks RJ,Matthews JP,et al.Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer[J].J Clin Oncol,2003,21(7):1285-1292.
9Young H,Baum R,Cremerius U,et al.Measurement of clinical and subclinical tumour response using[18F]-fluorodeoxyglucose and positron emission tomography:review and 1999 EORTC recommendations.European Or-ganization for Research and Treatment of Cancer (EORTC) PET Study Group[J].Eur J Cancer,1999,35(13):1773-1782.
10Shankar LK,Hoffman JM,Bacharach S,et al.Consensus recommendations for the use of ^18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials[J].J Nucl Med,2006,47 (6):1059-1066.
2Mountain CF. Revisions in the international system for staging lung cancer[J]. Chest,1997,111(6):lTlO 1717.
3Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system[J]. Chest,2009,136(1):260- 271.
4Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2002,54(4): 1024-1035.
5Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of lSF-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials[J] J Nucl Med,2006,47(6) :1059-1066.
6Wang Y, Ma S, Dong M, et al. Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT [ J ]. BMC Pulm Med, 2015, 15 : 20.
7Yamamoto T, Kadoya N, Shirata Y, et al. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy [ J ]. Radiat Oncol, 2015, 10: 35.
8Wang J, Mahasittiwat P, Wang KK, et al. Natural growth and disease progression of non-small cell lung cancer evaluated with 18F- fluorodeoxyglucose PET / CT [ J ]. Lung Cancer, 2012, 78 ( 1 ) : 51- 56.
9Ho TY, Chou PC, Yang CT, et al. Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma [ J]. Clin Nucl Med, 2015, 40( 6 ) : 295-299.
10Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using FDG PEG [ J ]. J Nuel Med, 1999, 40( 11 ) : 1771-1777.
